Amy Bachrodt sold $226k of MAZE
SVP, Finance at Maze Therapeutics, Inc.. 5,000 shares at an average of $45.20, traded Mar 2, 2026, filed Mar 3, 2026.
Score components
- +15RoleOfficer
- +13Trade size$226k at market
- +10Share of holdings soldSold 28% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002050422-26-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | MOption exercise Common Stock10b5-1 | +5,000 | $10.42 | $52k | 17,965 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -1,300 | $44.44 | $58k | 16,665 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -3,700 | $45.47 | $168k | 12,965 | Mar 3, 2026 |
| Mar 2, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 36,333 | Mar 3, 2026 |
| Mar 2, 2026 | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +32,000 | $0.00 | $0 | 32,000 | Mar 3, 2026 |
| Mar 2, 2026 | AGrant or award Restricted Stock Unitsderivative10b5-1 | +16,000 | $0.00 | $0 | 16,000 | Mar 3, 2026 |
Related signals
Other insiders at Maze Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | Maze Therapeutics, Inc. | Harold Bernstein President, R&D & CMO | $435k 16,141 shares | -100% | |
| 64Notable | Maze Therapeutics, Inc. | Jason Coloma V Chief Executive Officer | $932k 34,501 shares | -190% | |
| 12Weak | Maze Therapeutics, Inc. | Atul Dandekar CSBO | $203k 7,500 shares | -19% | |
| 48Moderate | Maze Therapeutics, Inc. | Harold Bernstein President, R&D & CMO | $255k 9,705 shares | -100% | |
| 68Notable | Maze Therapeutics, Inc. | Harold Bernstein President, R&D & CMO | $270k 10,295 shares | -51% | |
| 69Notable | Maze Therapeutics, Inc. | Jason Coloma V Chief Executive Officer | $594k 22,638 shares | -45% | |
| 50Moderate | Maze Therapeutics, Inc. | Phillips Courtney GC and Corp. Secretary | $105k 3,993 shares | -36% | |
| 46Moderate | Maze Therapeutics, Inc. | Atul Dandekar CSBO | $169k 6,434 shares | -17% | |
| 37Weak | Maze Therapeutics, Inc. | Harold Bernstein President, R&D & CMO | $426k 16,141 shares | -100% | |
| 49Moderate | Maze Therapeutics, Inc. | Jason Coloma V Chief Executive Officer | $907k 34,501 shares | -166% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.